Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Journal of Clinical Oncology, Vol 26, No 2 (January 10), 2008: pp. 290-296
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.13.0898

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Timmer-Bonte, J. N.H.
Right arrow Articles by Tjan-Heijnen, V. C.G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Timmer-Bonte, J. N.H.
Right arrow Articles by Tjan-Heijnen, V. C.G.

Modeling the Cost Effectiveness of Secondary Febrile Neutropenia Prophylaxis During Standard-Dose Chemotherapy

Johanna N.H. Timmer-Bonte, Eddy M.M. Adang, Evelien Termeer, Johan L. Severens, Vivianne C.G. Tjan-Heijnen

From the Departments of Medical Oncology, Pulmonary Diseases, and Epidemiology, Biostatistics & Health Technology Assessment, Radboud University Nijmegen Medical Centre, Nijmegen; Department of Health Organisation, Policy, and Economics, Maastricht University; Department of Clinical Epidemiology and MTA; and Department Internal Medicine, Division Medical Oncology, University Hospital Maastricht, Maastricht, the Netherlands

Corresponding author: J.N.H. Timmer-Bonte, MD, 452 Department of Medical Oncology/Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, the Netherlands; e-mail: J.Timmer{at}onco.umcn.nl

Purpose: Current guidelines (ie, by the American Society of Clinical Oncology and the European Organisation for Research and Treatment of Cancer) do not recommend secondary infection prophylaxis, whereas, in contrast, caregivers prefer secondary prophylaxis to chemotherapy dose reduction after an episode of febrile neutropenia (FN). Because granulocyte colony-stimulating factor (G-CSF) is expensive, this study investigates the economic consequences of secondary prophylactic use of different prophylactic strategies (antibiotics, antibiotics plus G-CSF, and a combined sequential approach) in a population at risk of FN, using a Markov model.

Methods: The input for the model is mainly based on the clinical outcome and patient-based cost data set (adopting the health care payer's perspective for the Netherlands) derived from a randomized study on primary prophylaxis in small-cell lung cancer (SCLC) patients; establishing mean cost of an episode FN of {euro}3,290 and prophylaxis of {euro}79 (antibiotics) ± {euro}1,616 (G-CSF) per cycle. The economic analysis was analyzed probabilistically using first- and second-order Monte Carlo simulation. The incremental cost-effectiveness ratio (ICER) was defined as cost per FN-free cycle.

Results: Secondary prophylaxis with antibiotics was the least expensive strategy (mean, {euro}4,496/patient). The strategy antibiotics plus G-CSF was most expensive (mean, {euro} 8,998/patient). Comparison of these two strategies resulted in an unacceptably high ICER ({euro}343,110 per FN-free cycle) in the Dutch context. In scenarios using higher FN-related costs (as found in the United States), the strategies are less distinct in their monetary effects, but still favor antibiotics.

Conclusion: This model-based economic analysis demonstrates that in the Netherlands and most likely also in the United States, if secondary prophylaxis is preferred, the strategy with antibiotics is recommended.

Supported by a research grant from the Dutch Healthcare Insurance Board (OG 99 053).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.






About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online